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Combination Therapy Approved for Melanoma
In January, the U.S. Food and Drug Administration (FDA) approved the targeted drug combination of trametinib (Mekinist; GlaxoSmithKline) and dabrafenib (Tafi nlar; GlaxoSmithKline) for treating patients with metastatic or unresectable melanoma with BRAF V600K or V600E mutations. Both drugs received approval as monotherapies in May 2013.
Trametinib and dabrafenib inhibit kinases in the RAS/RAF/MEK/ERK pathway. In clinical trials, patients treated with either of these singleagent therapies develop resistance to the drugs and have disease progression within 6 or 7 months, but their combined effect extends that time.
Keith Flaherty, MD, an oncologist at the Massachusetts General Hospital Cancer Center in Boston, says combination therapies expand the effi cacy of the fi rst generation of targeted drugs, the earliest of which entered treatment regimens more than a dozen years ago.
"Numerous two-drug combinations are being evaluated in ongoing drug trials now," he says, representing the beginning of a coming wave of multidrug therapies. "I think 2014 will witness the fi rst wave of triplet targeted regimens as well."
Targeted therapies often benefi t only a small fraction of a cancer population, but combination therapies may prolong response times and benefi t additional patient subgroups.
In the approval statement, the FDA cited results from a phase II open-label clinical trial, led by Flaherty, involving 162 patients with metastatic melanoma that expressed a BRAF mutation, most of whom were previously untreated. Participants received either dabrafenib alone or dabrafenib in combination with trametinib. Patients who received the highest combination dose-150 mg of dabrafenib twice daily with 2 mg of trametinib once daily-had an objective response rate of 76% and a median progression-free survival (PFS) of 9.4 months, compared with 54% and 5.8 months in patients treated only with dabrafenib. Overall survival data are not yet available.
On January 24, after FDA approval was granted, GlaxoSmithKline announced that the combination met its primary endpoint of PFS in a phase III trial that compared the combination to dabrafenib plus a placebo. PFS, response rate, and interim overall survival results were consistent with those seen in earlier studies, according to the company. Full results will be presented at an upcoming scientifi c meeting.
When targeted therapy is appropriate for a patient, the newly approved combination clearly has some advantages over single agents and "should be considered as an option for standard of care," says Mario Sznol, MD, an oncologist at the Yale Cancer Center in New Haven, CT. Data from the phase II trial, which was published in 2012, "really showed a dramatic improvement in progression-free survival for the combination," with tolerable toxicity.
The next diffi cult decision clinicians will face, says Sznol, is determining whether to offer the combination targeted therapy or immunotherapy to a patient with a BRAF mutation-or offer both, one after the other.
"We may need a randomized trial to determine which sequence of therapies, if sequencing is indeed the best approach, would lead to the best outcome in the majority of patients." ■
$540 Million Gift Boosts Cancer Research
In one of the largest single philanthropic gifts ever made to support cancer research, Ludwig Cancer Research, based in New York, NY, announced that it will disburse $540 million from the estate of the late shipping magnate Daniel K. Ludwig equally to six institutions.
In its January 6 announcement, the organization said that the money would fund cancer research at Ludwig Centers at Harvard University, Johns Hopkins University, the Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center, Stanford University, and the University of Chicago, based on stipulations Ludwig made before his death in 1992.
"Daniel Ludwig viewed cancer as a major challenge to mankind, which requires a comprehensive and concerted 
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we use it, so we can be creative, innovative, and use as much 'out-of-the-box' thinking as we want to."
Greene and his colleagues plan to use the funds to recruit senior investigators and fund new initiatives to bolster their effort to better understand the genesis, progression, and management of cancer metastasis. Other centers are focused on areas ranging from immunotherapy and stem cell research to cancer prevention and early detection. ■
Budgets Up at NIH, NCI, and FDA
After a fi scally challenging year, scientifi c and medical research will feel some budgetary relief with the new federal spending bill signed into law in mid-January by President Obama, totaling $1.1 trillion for fi scal year 2014. Under the new budget, the U.S. Food and Drug Administration (FDA) will receive $2.552 billion, $166 million more than its post-sequestration 2013 budget, a 7% increase. Funding for the NIH will increase by $1 billion to $29.9 billion, a 3.5% increase, and funding for the National Cancer Institute (NCI) will increase by $140 million to $4.923 billion, a 2.9% increase.
Sequestration, which amounted to a 5% reduction of the NIH FY2013 budget applied evenly across all programs, projects, and activities, had wide-ranging effects. According to NIH Director Francis Collins, MD, PhD, the cuts not only increased competition for new grants, making it harder for new investigators and new ideas to be funded, but also slashed funds from existing grants that were already operating on tight budgets.
For the FDA, the bill goes beyond restoring the budget losses due to sequestration, although a large portion of the increase will cover foodsafety activities mandated by a 2011 law. However, other agencies weren't as lucky. The NIH budget falls $714 million short of pre-sequestration funding levels. The NCI budget increase makes up only about half of sequestration losses. In fact, in real dollars, NCI's FY2014 budget falls short of its FY2009 budget of $4.968 billion.
"We should clearly express our appreciation to the Congress for being able to do that much in an incredibly with an initial $120 million endowment, followed by donations of an additional $240 million for endowed professorships and operating expenses.
"We've had a good return on the investment," says McDermott. "The Centers have already generated the fi rst comprehensive maps of the genomic landscape, paved the way for 'smart drugs' and immunotherapy, and laid the foundation to treat certain rare and fast-spreading types of cancers."
The latest gift, which completes Ludwig's original endowment plan for the centers, is designed to offer funding in perpetuity by allowing each center to invest $90 million and draw an estimated $4 to $5 million in interest annually.
"Now that these Ludwig Centers have been securely established, the objective is to extend and strengthen the collaboration between them and the various branches of the Institute," says McDermott.
The centers combined with the Institute make up Ludwig Cancer Research, a nonprofi t, international, collaborative network of acclaimed scientists with an endowment of $1.2 billion. To date, Ludwig Cancer Research has dedicated more than $2.5 billion to cancer research worldwide.
"The donation provides us an incredible opportunity," says Geoffrey Greene, PhD, codirector of the Ludwig Center at the University of Chicago in Illinois. "We're not restricted in how diffi cult environment," says Edward J. Benz Jr., MD, president of Dana-Farber Cancer Institute in Boston, MA. "On the other hand, it's a partial make-up. It is not a solution to the fundamental weakening of the research enterprise that has resulted from a long history of dwindling funding that was exacerbated by sequestration."
At Dana-Farber, sequestration delayed recruitment and indefi nitely postponed development of various research centers. "Money that that might have been used for new projects, new ideas, or for recruiting new investigators had to be diverted toward making up for the losses to existing labs," says Benz.
The sequestration cuts of FY2013 came on top of budget cuts for the NIH and NCI that began in FY2011. Even without taking into account outright budget cuts, the NIH budget had not kept pace with biomedical infl ation, an estimated increase in the prices of research equipment and supplies, in a decade. In January 2013, the NIH projected biomedical infl ation levels of 2.7% for FY2014 and 2.9% for FY2015.
"Resources are constrained, but there is still a lot of federal and nonfederal money being spent on cancer research," says Benz. "It's incumbent on us to fi nd the best way to use existing funding to make the biggest impact on patients." ■
Report Links Smoking to Poor Cancer Outcomes
Fifty years ago, the landmark 1964 report Smoking and Health, issued by U.S. Surgeon General Luther Terry, MD, fi rst linked smoking to lung cancer. The latest report, issued in January by Acting Surgeon General Boris Lushniak, MD, MPH, and available at www. surgeongeneral.gov, highlights successes of the resulting anti-tobacco movement and expands the long list of smokingrelated health problems to include colorectal and liver cancers, diabetes, and rheumatoid arthritis, among others.
The comprehensive new report-the 32nd such document-is also the fi rst to offer evidence documenting the harms of continued smoking for people with cancer. It notes that smoking increases all-cause mortality by at least 50% and cancer-specifi c mortality by 61% in cancer patients. 
